This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Calidi Biotherapeutics’s 8K filing here.
Calidi Biotherapeutics Company Profile
Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.
Featured Stories
- Five stocks we like better than Calidi Biotherapeutics
- What is the FTSE 100 index?
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- Short Selling: How to Short a Stock
- Tesla Stock: Buy the Dips, Sell the Rips
